podophyllotoxin has been researched along with Cystadenocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barlow, JJ; Lele, SB | 1 |
| Bishop, JF; Campbell, JJ; Day, A; Hillcoat, BL; Pepperell, R; Quinn, MA | 1 |
2 other study(ies) available for podophyllotoxin and Cystadenocarcinoma
| Article | Year |
|---|---|
Etoposide (VP-16) plus cisplatin (DDP): a new active chemotherapeutic combination in patients with stage III-IV ovarian adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Podophyllotoxin; Prognosis | 1986 |
Phase II trial of VP-16-213 in advanced ovarian carcinoma.
Topics: Administration, Oral; Aged; Carcinoma; Cisplatin; Cystadenocarcinoma; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Middle Aged; Nausea; Ovarian Neoplasms; Podophyllotoxin; Vomiting | 1985 |